Gastrointestinal Cancer

Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.

The addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.

Pembrolizumab as an adjuvant therapy compared with placebo continued to showcase an impressive disease-free survival benefit in patients with clear cell renal cell carcinoma following nephrectomy, with improvement observed across subgroups.

The dismutase mimetic avasopasem manganese was found to improve overall survival, progression-free survival, local disease control, time to metastases, and tumor response rate compared with placebo in patients with unresectable or borderline resectable locally advanced pancreatic cancer who were undergoing stereotactic body radiation.

The FDA has accepted for review a biologics license application for tislelizumab as a potential therapeutic option in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma following previous systemic therapy.

Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.

Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

The National Medical Products Administration in China has approved pembrolizumab for use in combination with platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or gastroesophageal junction cancer.

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

The risk of cancer-specific death was significantly higher than the risk of noncancer death in patients with neuroendocrine tumors, despite the reported heterogeneity by primary tumor site.

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

E. Gabriela Chiorean, MD, discusses some of the recent developments in pancreatic cancer, HCC, and NETs, as well as multidisciplinary approaches for treating these patients.

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).